Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235365 | 1.00 | MAPT (0.37) | MAPTALDH1A1HPGDMEN1GAA | |
| SCHEMBL2234256 | 0.82 | NOTUM (0.38) | MAPTALDH1A1HPGDMEN1GAA | |
| SCHEMBL2235772 | 0.79 | IDH1 (0.38) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2234596 | 0.79 | GABRG2 (0.34) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2234603 | 0.79 | GABRG2 (0.34) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2237866 | 0.77 | NOTUM (0.42) | — | |
| SCHEMBL2236516 | 0.76 | SRD5A1 (0.43) | MAPTMEN1KMT2ASMN1; SMN2SRD5A1 | |
| SCHEMBL2235093 | 0.75 | GABRG2 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2235080 | 0.75 | GABRG2 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2232987 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HPGDLMNASRD5A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | MAPT 4511/4885ALDH1A1 4182/4885HPGD 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.